Nature’s Toolbox, Inc. (NTx), a life science company developing domestically-sourced biomanufacturing solutions for the delivery of personalized therapeutics and biologics, secured $15 million in venture debt from J.P. Morgan. The financing will fuel the deployment of NTx systems across major pharmaceutical, governmental, and clinical organizations.
Read also – AMP Raises $91 Mn Series D Funding to Revolutionize Waste
“As we prepare for the commercial expansion of our distributed biomanufacturing technology, this financing will help us broaden our reach and fulfill our mission to revolutionize biomaterials production by making it more accessible, scalable, and cost-effective,” said Jamie Coffin, CEO of NTx. “We are excited to have the support of J.P. Morgan and look forward to leveraging their expertise in working with growth-stage life sciences companies.”
Read also – Nuvig Therapeutics Raises $161 Mn Series B Financing
While conventional manufacturing processes and supply chain instability have slowed progress and increased the cost of developing life-saving vaccines and biologics, NTx platforms will utilize U.S. made raw materials and help create an end-to-end domestic supply chain for critical biomaterials. The system not only reduces costs and simplifies the process, but also eliminates harmful byproducts, making it significantly more sustainable than traditional batch methods.
“J.P. Morgan is proud to work with NTx as they continue to scale,” said Liz Crum, Co-Head of West Life Sciences within J.P. Morgan’s Innovation Economy business. “It’s an exciting time to be working with life sciences companies, and we look forward to supporting the role NTx plays in transforming the way biomaterials are produced and expediting the delivery of personalized therapies.”
About NTx
Nature’s Toolbox, Inc. (NTx) is advancing the healthcare industry with their next generation biomanufacturing solutions. NTx, based in Rio Rancho, New Mexico, is developing innovative systems like NTxpress® and NTxscribe® to enable manufacturing of mRNA vaccines and protein therapeutics in an eco-friendly and sustainable way. These easily scalable processes enable NTx’s platform to scale from personalized medicine dosage to pandemic volume.
